Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23079718 | 0.94 | NPC1 (0.60) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL14523837 | 0.87 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL11368923 | 0.87 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL31170 | 0.86 | NPC1 (0.81) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL13426596 | 0.85 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL15783208 | 0.85 | NPC1 (0.57) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL14030921 | 0.84 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL21544993 | 0.84 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL24250386 | 0.84 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL31476 | 0.84 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-10930859-B2 | Phenanthroquinazoline-core compounds | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-20200303659-A1 | PHENANTHROQUINAZOLINE-CORE COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-24 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10580996-B2 | Polycyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2020-03-03 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| CN-109180590-A | A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free | 福建医科大学 | 2019-01-11 | — | — | CN | disclosed |
| US-9999619-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-17 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20100096982-A1 | Novel organic electroluminescent compounds and organic electrouminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-04-22 | — | — | US | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20090230852-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-09-17 | — | — | US | disclosed |
| US-20090230852-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-09-17 | — | — | US | disclosed |
| US-7332516-B2 | Geminally di-substituted NSAID derivatives as Aβ42 lowering agents | MERCK + CO., INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332516-B2 | Geminally di-substituted NSAID derivatives as Aβ42 lowering agents | MERCK + CO., INC. (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100096982-A1 | Novel organic electroluminescent compounds and organic electrouminescent device using the same | OCIAD1, OR10J3, ORMDL3 | NPC1 2861/4885RAB9A 646/4885MEN1 3162/4885 |
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | NPC1 830/4885RAB9A 2162/4885MEN1 1986/4885 |
| US-20090230852-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OXER1, L1CAM, RPL41 | NPC1 2149/4885RAB9A 2994/4885MEN1 2284/4885 |
| US-10930859-B2 | Phenanthroquinazoline-core compounds | TOP1, TOP2A, BICRA | NPC1 844/4885RAB9A 2212/4885MEN1 173/4885 |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | RPL36, RPL39, RPL36A | NPC1 3063/4885RAB9A 1843/4885MEN1 3994/4885 |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | NPC1 2971/4885RAB9A 708/4885MEN1 2382/4885 |
| US-20180138421-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY2, NR2E3, CRY1 | NPC1 2060/4885RAB9A 3322/4885MEN1 396/4885 |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | NPC1 1582/4885RAB9A 3169/4885MEN1 4462/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | NPC1 2971/4885RAB9A 708/4885MEN1 2382/4885 |
| US-10580996-B2 | Polycyclic compound and organic light-emitting element comprising same | CRY2, NR2E3, CRY1 | NPC1 2060/4885RAB9A 3322/4885MEN1 396/4885 |
| US-20200303659-A1 | PHENANTHROQUINAZOLINE-CORE COMPOUNDS | TOP1, TOP2A, BICRA | NPC1 844/4885RAB9A 2212/4885MEN1 173/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | NPC1 2925/4885RAB9A 693/4885MEN1 1677/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | NPC1 2971/4885RAB9A 708/4885MEN1 2382/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | NPC1 887/4885RAB9A 2260/4885MEN1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.